CONTEXT: In patients with coexisting iron-deficiency anemia and subclinical hypothyroidism, anemia does not adequately respond to oral iron therapy. OBJECTIVE: We studied whether iron-deficiency anemia might indicate treatment of subclinical hypothyroidism. DESIGN: PATIENTS were assigned to a control or experimental group: 240 mg/d oral iron alone (iron group) or 240 mg/d oral iron plus 75 microg/d levothyroxine (iron/levothyroxine group). Levels of hemoglobin, hematocrit, red blood cell count, serum iron levels, ferritin, total iron-binding capacity, TSH, and free T(4) were measured before and after treatment. SETTING: The study was conducted at a university hospital outpatient clinic. PATIENTS: Fifty-one patients with coexisting iron-deficiency anemia and subclinical hypothyroidism participated in the study. INTERVENTION: PATIENTS were treated as described above in either the iron group or the iron/levothyroxine group. MAIN OUTCOME MEASURE: A clinically satisfactory increase in hemoglobin was regarded as successful. RESULTS:Mean hemoglobin levels increased by 0.4 g/dl in the iron group [95% confidence interval (CI) 0.2-0.7, P = 0.001], whereas it increased by a mean of 1.9 g/dl in the iron/levothyroxine group (95% CI 1.5-2.3, P < 0.0001). The increase in serum iron was greater in the iron/levothyroxine group by a mean of 47.6 microg/dl (95% CI 34.5-60.6, P < 0.0001). Increases in hemoglobin, red blood cells, hematocrit, and serum ferritin levels after treatment were statistically significantly greater in the iron/levothyroxine group (P < 0.0001). Starting hemoglobin and increase in hemoglobin were negatively correlated in the iron/levothyroxine group (r = -0.531, P = 0.006). CONCLUSIONS:Subclinical hypothyroidism should be treated in iron-deficiency anemia patients when both conditions coexist. This would provide a desired therapeutic response to oral iron replacement and prevent ineffective iron therapy.
RCT Entities:
CONTEXT: In patients with coexisting iron-deficiency anemia and subclinical hypothyroidism, anemia does not adequately respond to oral iron therapy. OBJECTIVE: We studied whether iron-deficiency anemia might indicate treatment of subclinical hypothyroidism. DESIGN:PATIENTS were assigned to a control or experimental group: 240 mg/d oral iron alone (iron group) or 240 mg/d oral iron plus 75 microg/d levothyroxine (iron/levothyroxine group). Levels of hemoglobin, hematocrit, red blood cell count, serum iron levels, ferritin, total iron-binding capacity, TSH, and free T(4) were measured before and after treatment. SETTING: The study was conducted at a university hospital outpatient clinic. PATIENTS: Fifty-one patients with coexisting iron-deficiency anemia and subclinical hypothyroidism participated in the study. INTERVENTION: PATIENTS were treated as described above in either the iron group or the iron/levothyroxine group. MAIN OUTCOME MEASURE: A clinically satisfactory increase in hemoglobin was regarded as successful. RESULTS: Mean hemoglobin levels increased by 0.4 g/dl in the iron group [95% confidence interval (CI) 0.2-0.7, P = 0.001], whereas it increased by a mean of 1.9 g/dl in the iron/levothyroxine group (95% CI 1.5-2.3, P < 0.0001). The increase in serum iron was greater in the iron/levothyroxine group by a mean of 47.6 microg/dl (95% CI 34.5-60.6, P < 0.0001). Increases in hemoglobin, red blood cells, hematocrit, and serum ferritin levels after treatment were statistically significantly greater in the iron/levothyroxine group (P < 0.0001). Starting hemoglobin and increase in hemoglobin were negatively correlated in the iron/levothyroxine group (r = -0.531, P = 0.006). CONCLUSIONS:Subclinical hypothyroidism should be treated in iron-deficiency anemiapatients when both conditions coexist. This would provide a desired therapeutic response to oral iron replacement and prevent ineffective iron therapy.
Authors: Connie M Rhee; Steven Kim; Daniel L Gillen; Tolga Oztan; Jiaxi Wang; Rajnish Mehrotra; Sooraj Kuttykrishnan; Danh V Nguyen; Steven M Brunelli; Csaba P Kovesdy; Gregory A Brent; Kamyar Kalantar-Zadeh Journal: J Clin Endocrinol Metab Date: 2015-01-29 Impact factor: 5.958
Authors: Xiaofei Gao; Hsiang-Ying Lee; Wenbo Li; Randall Jeffrey Platt; M Inmaculada Barrasa; Qi Ma; Russell R Elmes; Michael G Rosenfeld; Harvey F Lodish Journal: Proc Natl Acad Sci U S A Date: 2017-09-01 Impact factor: 11.205
Authors: Connie M Rhee; Gregory A Brent; Csaba P Kovesdy; Offie P Soldin; Danh Nguyen; Matthew J Budoff; Steven M Brunelli; Kamyar Kalantar-Zadeh Journal: Nephrol Dial Transplant Date: 2014-02-25 Impact factor: 5.992
Authors: Mee Kyoung Kim; Hyuk Sang Kwon; Ki-Hyun Baek; Je Hoon Lee; Woo Chan Park; Hyung Sun Sohn; Kwang-Woo Lee; Ki-Ho Song Journal: Diabetes Care Date: 2010-09-07 Impact factor: 19.112
Authors: Robert S Du Puy; Rosalinde K E Poortvliet; Simon P Mooijaart; David J Stott; Terry Quinn; Naveed Sattar; Rudi G J Westendorp; Patricia M Kearney; Vera J C McCarthy; Stephen Byrne; Nicolas Rodondi; Oliver Baretella; Tinh-Hai Collet; Diana van Heemst; Olaf M Dekkers; J Wouter Jukema; Johannes W A Smit; Jacobijn Gussekloo; Wendy P J den Elzen Journal: J Clin Endocrinol Metab Date: 2022-05-17 Impact factor: 6.134
Authors: Marcello Maggio; Francesca De Vita; Alberto Fisichella; Fulvio Lauretani; Andrea Ticinesi; Graziano Ceresini; Anne Cappola; Luigi Ferrucci; Gian Paolo Ceda Journal: Int J Endocrinol Date: 2015-12-08 Impact factor: 3.257